While C4 Therapeutics Inc has overperformed by 1.00%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, CCCC fell by -43.61%, with highs and lows ranging from $4.26 to $1.09, whereas the simple moving average fell by -2.42% in the last 200 days.
On December 02, 2025, TD Cowen started tracking C4 Therapeutics Inc (NASDAQ: CCCC) recommending Buy. A report published by Barclays on September 17, 2025, Initiated its previous ‘Overweight’ rating for CCCC. Stephens also Upgraded CCCC shares as ‘Overweight’, setting a target price of $6 on the company’s shares in a report dated September 15, 2025. Guggenheim Initiated an Buy rating on September 04, 2025, and assigned a price target of $8. Wells Fargo December 19, 2024d its ‘Equal Weight’ rating to ‘Overweight’ for CCCC, as published in its report on December 19, 2024. Stephens’s report from November 18, 2024 suggests a price prediction of $4 for CCCC shares, giving the stock a ‘Equal-Weight’ rating. JP Morgan also rated the stock as ‘Neutral’.
Analysis of C4 Therapeutics Inc (CCCC)
Further, the quarter-over-quarter decrease in sales is -26.90%, showing a negative trend in the upcoming months.
In order to gain a clear picture of C4 Therapeutics Inc’s future performance, a variety of well-rounded analysis and research techniques can be applied, with equity being the most critical. The goal here is to ensure that your current return on equity of -59.98% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 5.76, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
An average volume of 2.13M can be a very valuable indicator of volatility for CCCC stock. On a monthly basis, the volatility of the stock is set at 7.47%, whereas on a weekly basis, it is put at 7.54%, with a loss of -17.81% over the past seven days. Furthermore, long-term investors anticipate a median target price of $11.14, showing growth from the present price of $2.03, which can serve as yet another indication of whether CCCC is worth investing in or should be passed over.
How Do You Analyze C4 Therapeutics Inc Shares?
In addition to the fundamentals, you should also consider how many employees own shares in the company. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 19.13%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 57.44% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
CCCC shares are owned by institutional investors to the tune of 57.44% at present.
